4DMT Announces New Employment Inducement Grants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
4D Molecular Therapeutics (FDMT) granted one new non-executive employee 21,800 restricted stock units on November 10, 2026, as an employment inducement. Restricted stock units are equity compensation awards. The board’s compensation committee approved the grants under the company’s amended 2025 Employment Inducement Award Plan, pursuant to Nasdaq Global Market Rule 5635(c)(4) for equity grants that induce new employees to join the company.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.21,800 restricted stock units granted to one new non-executive employee represent potential shareholder dilution.
Key Figures
- Restricted stock units granted
- 21,800 RSUs
- Granted to one new non-executive employee
Historical Context
-
Equity awards for 13 new employees included options and restricted stock units.
-
Seven new non-executive employees received 96,000 restricted stock units under the same plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 10, 2026, the compensation committee of the Company’s board of directors granted one new non-executive employee 21,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What employment inducement awards did 4D Molecular Therapeutics grant on November 10, 2026?
4D Molecular Therapeutics granted 21,800 restricted stock units to one new non-executive employee on November 10, 2026. The compensation committee approved the awards under the company’s amended 2025 Employment Inducement Award Plan.